Introduction
The Wilms' tumour suppressor (WT1) gene encodes a nuclear protein containing four C-terminal C 2 H 2 zincfinger motifs that are capable of DNA, RNA and protein binding. WT1 expression is confined to the developing urogential tract, the mesothelial cells and early haematopoietic lineages. Positionally cloned as being responsible for the Wilms' tumour component of the WAGR syndrome Gessler et al., 1990) , mutations in WT1 are also seen in sporadic Wilms' tumour Little and Wells, 1997) , Denys-Drash syndrome (Pelletier et al., 1991a; Little and Wells, 1997) , some cases of acute myeloid leukaemia (Pritchard-Jones et al., 1994; King-Underwood et al., 1996) , desmoplastic round cell tumour (Ladanyi and Gerald, 1994) , granulosa cell tumour (Pelletier et al., 1991b) and mesothelioma (Park et al., 1993) . Genotype-phenotype analyses of these conditions, together with gene knockouts in mice, have revealed at least three distinct roles for WT1 during kidney development. These are (i) survival of the metanephric mesenchyme (MM), (ii) mesenchymal to epithelial transition (MET) of that mesenchyme to form the nephrons and (iii) maintenance of ongoing renal function via continued expression in the podocytes of the glomeruli. WT1 is one of the first genes expressed during the development of the MM, which gives rise to the permanent kidney. WT1 expression here is essential for the survival of the MM, and a total knockout of WT1 results in total renal and gonadal agenesis (Kreidberg et al., 1993) . A role for WT1 in the process of MET, which results in nephron endowment, is implied both by WT1 upregulation during this event and the blastemal proliferation and arrested epithelialization seen in Wilms' tumours. Finally, Denys-Drash syndrome patients (Denys et al., 1967; Drash et al., 1970) , who carry a single mutant copy of the WT1 gene constitutionally, suffer early onset nephropathy as a result of mesangial sclerosis suggesting that the ongoing expression of WT1 by the podocytes is essential for glomerular function after birth.
Located in the nucleus and containing C-terminal zinc-finger motifs, it has been assumed that the biological roles of WT1 would result from its activity as a transcription factor. The WT1 gene actually encodes multiple protein isoforms as a result of alternate splicing and several transcriptional start sites Bruening and Pelletier, 1996; Scharnhorst et al., 1999) . The most commonly described isoforms are four 52/54 kDa proteins that vary due to the presence of exon 5 (51 bp/17 amino acids) and the use of an alternative splice donor site in exon 9 resulting in the insertion of 9 bp that encodes the amino-acids lysinethreonine-serine (KTS). These four isoforms are commonly referred to as WT1 isoforms A (no exon 5/ no KTS), B ( þ exon 5/ no KTS ), C (no exon 5/ þ KTS ) and D ( þ exon 5/ þ KTS). The ratios of these isoforms has been found to remain stable temporally and spatially . This observation together with the ability of WT1 isoforms to dimerize (Reddy et al., 1995b; Holmes et al., 1997) suggests that WT1 action is a product of the synergistic activity of multiple WT1 isoforms. Despite this fact, the similarity of WT1 C 2 H 2 zinc-fingers 2-4 to those of zinc-fingers 1-3 of early growth response gene 1 (EGR1) (Madden et al., 1991) has driven the identification of putative WT1 target genes. Over 50 genes with EGR1-like WT1-binding sites in their promoters have been proposed as putative WT1 target genes, including WT1 itself (Lee and Haber, 2001) . Mutations in none of these putative targets have been associated with the onset of Wilms' tumour, a condition in which direct mutation of WT1 itself can only account for 10% of tumours.
The advent of expression profiling, whether cDNA or oligo-based, has allowed the parallel examination of the expression levels of tens of thousands of genes under different parameters. While more commonly exploited in the analysis of cancer biology, expression profiling is also proving valuable in the dissection of developmental processes, including sex determination (Grimmond et al., 2000) . Expression profiling has been applied to WT1 biology both to investigate the validity of previously proposed WT1 targets, and to identify additional physiological targets. Generally, this has involved the generation of stable cell lines (including Saos2, U2OS, G401, HEK293) expressing one of the common WT1 isoforms often under an inducible promoter (Thate et al., 1998; Lee et al., 1999; Lee and Pelletier, 2001; Sim et al., 2002) . The universal conclusion drawn from expression profiling analyses of the effect of WT1 expression is that few, if any, of the previously proposed targets of WT1 are indeed physiologically relevant. Additionally, it has been observed that WT1 induction has little effect on the level of expression of most genes. Nevertheless, these studies have revealed a couple of novel WT1 target genes, including amphiregulin (Lee et al., 1999) , connective tissue growth factor (Stanhope-Baker and Williams, 2000) , vitamin D receptor (Lee and Pelletier, 2001 ) and Wnt4 (Sim et al., 2002) .
There are a number of caveats to such approaches, both of a general nature and more particularly applying to WT1. With respect to the latter, it has been clearly demonstrated that the effect of WT1 expression is context-dependant, varying with cell line, isoform and promoter (Reddy et al., 1995a) . This is likely to result in part from the ability of WT1 to interact with many other proteins whose presence will in turn vary from cell line to cell line (reviewed in Little et al., 1999) . Indeed, within the male gonadal ridge, the ability of the transcription factor steroidogenic factor 1 (SF-1) to activate the transcription of mullerian inhibitory substance (MIS) relies upon a protein-protein interaction with WT1 (Nachtigal et al., 1998) . However, in the female gonadal ridge, this interaction with SF-1 is competed off by the presence of the Dax1 protein (Nachtigal et al., 1998) . The context dependence of WT1 activity also stems from the ability of WT1 isoforms to directly interact with each other via domains with the N-terminal end of the proteins (Reddy et al., 1995b; Holmes et al., 1997) . The expression of a single isoform of WT1 in the absence of others is likely to result in a nonphysiological result as the biological actions of WT1 are reliant upon the maintenance of the correct ratios of each isoform. Denys-Drash syndrome can result from a reduction in the production of þ KTS-containing isoforms from one WT1 allele (Little and Wells, 1997; Hammes et al., 2001) . It has also been reported that Wilms' tumour itself is associated with an increase in the exon 5-containing isoforms of the protein (Simms et al., 1995) .
In this study, we sought to improve upon previous analyses of WT1 target genes using profiling by comparing the induction of WT1 with the repression of WT1. To do so, we created tetracycline-inducible WT1-A-and WT1-D-expressing HEK293 cell lines and performed cDNA microarray-based expression profiling over a 48 h time course. We also generated a stable transfectant of the mouse mesonephric cell line, M15, expressing a full-length antisense WT1 construct that abolished the endogenous production of all four major WT1 isoforms. We have concentrated on the overlapping complimentary gene expression changes seen after WT1 induction versus WT1 repression. In this way, we have highlighted the mevalonate pathway of cholesterol biosynthesis as a physiological target for WT1.
Results

Cell lines with and without WT1 expression
To better understand the developmental and tumorigenic function of WT1, it is necessary to identify the downstream target genes it regulates. The use of developmentally relevant cell lines allows the identification of legitimate downstream gene targets as these cells contain the correct combination of cofactors required for target binding. In this study, two different embryonic kidney cell lines, with and without WT1 expression, were expression profiled with the aim of identifying WT1 target genes. The first cell line used was human embryonic kidney 293 (HEK293) cells, which represent a late stage of kidney epithelial development (Valerius et al., 2002) . Endogenous WT1 transcripts could not be detected in these cells by RT-polymerase chain reaction (PCR) or Northern blot analysis (data not shown). HEK293 cells with inducible WT1 expression were made using the Tet-On system (Clontech) adapted from that of Bujard and co-workes (Gossen and Bujard, 1992) . Full-length WT1-A or WT1-D was cloned into a Tet-responsive vector and transfected into modified HEK293 Tet-On cells that express the Tet-transactivator (referred to as parental HEK293). Mutiple transfectants were tested to identify clones that had good induction in response to doxycycline and minimal leakage in the absence of doxycycline. WT1 expression was induced by the addition of doxycycline and cells were harvested at eight time points from 0 to 48 h. Successful induction of protein was confirmed by Western blot at each time point (Figure 1a ). The second cell line used, M15, is a murine mesonephric (mesonephros-derived) cell line that endogenously expresses all WT1 isoforms (Larsson et al., 1995a) . M15 cells were stably transfected with a full-length WT1 antisense transcript construct. Western analysis and immunofluorescence demonstrated a stable repression of WT1 protein production in recombinants (Figure 1b and c) .
Expression profiling for WT1-responsive genes
Ontario Cancer Institute (OCI) human 19 K 2.2. microarrays were used to compare gene expression profiles of parental HEK293 cells with HEK293 induced to express WT1-A or WT1-D over a 48 h time course. cDNA derived from induced HEK293 cells at each time point (labelled with Cy3-dUTP (green)) was compared back to cDNA from parental HEK293 Tet-On cells (Cy5-dUTP (red)). The arrays at time points 0, 0.5 and 24 h were repeated and a dye reversal was also performed for the 24 h time point. The OCI cDNA arrays represent approximately 19 008 known genes and expressed sequence tags (ESTs). As a control, the parental HEK293 Tet-On cell line, which did not contain the Tet-responsive vector, was induced with doxycycline for 30 min and 48 h, and then expression profiled to identify genes that are transcriptional altered by the addition of doxycycline. As a result, 1145 genes were excluded from the WT1 time-course experiment based on the fact that they were changed at least 1.8-fold by the addition of doxycycline (data not shown).
Of the 19 008 genes represented on the OCI arrays, 70 genes (43 up and 27 down) were identified as being differentially expressed by 1.8-fold or greater in more than four of the eight time points in response to WT1-A induction and 123 genes (86 up and 37 down) in response to WT1-D. These genes are represented in Figure 1d . The most dramatic changes in expression after the induction of WT1 were seen at the later time points (24 and 48 h). The majority of genes upregulated or downregulated by one isoform of WT1 were also differentially expressed in response to the other isoform in at least one time point. Overall, a total of 17 genes were upregulated and 10 were downregulated (1.8-fold or greater) by both WT1 isoforms in more than four of the eight time points analysed. A summary of those genes that were differentially expressed by both isoforms Table 1 . This group of genes includes enzymes involved in the production of cholesterol such as isopentenyl diphosphate delta isomerase (IDI1) and lanosterol synthase (LSS).
A second expression profiling screen for WT1 target genes was undertaken using SRC mouse NIA version 1 arrays containing 15 264 cDNAs. The clone set on this array represents ESTs from pre-and peri-implantation embryos, embryonic day (E) 12.5 female gonad/mesonephros, and newborn ovary (Tanaka et al., 2000) . RNA from parental M15 cells was compared with M15 cells transfected with a WT1 antisense construct. This Figure 2a ). The most dramatically changed cDNA from this list was stearoyl Co-A destaurase 2 (SCD2), which was upregulated 15-fold by repression of WT1 expression indicating that WT1 normally acts to repress this gene. Interestingly, IDI1 was also downregulated by WT1 in this experiment.
The characterization of WT1 as a transcriptional repressor of genes containing the GC-rich EGR1 sequence within their promoters has led to the identification of a large number of potential target genes, whose promoters are repressed by ectopic expression of WT1 in transient transfection assays (Lee and Haber, 2001) . In total, 26 of these candidate target genes were represented on the OCI and NIA microarrays. We were unable to confirm significant (two-fold or greater) changes in the majority of these genes (including EGR1, IGF2, Midkine and IGF1R) in response to induction or repression of WT1 (data not shown). In addition, there was no change in genes that play an important role in kidney development, some of which have been postulated to interact with WT1, including Pax8 and BMP7. The only WT1 putative target genes that showed a significant change in WT1 represses mevalonate genes FK Rae et al expression were c-myc and ornithine decarboxylase (ODC), which were both upregulated by WT1. Although c-myc has previously been shown to be repressed by WT1 (Hewitt et al., 1995) , studies have shown that WT1 can either activate or repress GC-rich promoter reporters, depending on experimental conditions (Reddy et al., 1995a) . In fact, WT1-A has been reported to activate or repress the ODC promoter depending on the cell line used (Moshier et al., 1996; Li et al., 1999) . Amphiregulin and podocalyxin, both recently identified as WT1 target genes (Lee et al., 1999; Palmer et al., 2001) , were not present on either the OCI or SRC arrays.
Mevalonate pathway
The results from these two expression profiling experiments were compared to identify complementary commonalities between the two (Table 3) . Although the two clone sets did not overlap completely, the most obvious agreement between them was the repression by WT1 of genes involved in cholesterol and fatty acid synthesis. Induction of both WT1-A and D in HEK293 cells resulted in the repression of IDI1 and LSS, which are both enzymes involved in cholesterol synthesis via the mevalonate pathway. Analysis of the expression profiling results for other genes involved in cholesterol synthesis revealed that farnesyl diphosphate farnesyltransferase (FDFT1) and farnesyl diphosphate synthase (FDPS) were also downregulated in several time points after induction of WT1 (Figure 2b ). These results were further verified by Northern blot analysis (Figure 2a and c). Interestingly, induction of WT1-A and D increased the expression of high-density lipoprotein-binding protein, a protein that may function to remove excess cellular cholesterol (McKnight et al., 1992) . Conversely, repression of WT1 in M15 cells increased the production of IDI1 and squalene epoxidase. In addition, SCD2 was also increased in response to repression of WT1. SCD2 is a central lipogenic enzyme catalysing the synthesis of monounsaturated fatty acids, which are components of membrane phophoslipids, triglycerides, wax esters and cholesterol esters. An overview of the role of these genes in the cholesterol and fatty acid synthetic pathways is presented in Figure 3 . The entire programe of cholesterol and fatty acid synthesis is regulated by the sterol regulatory element-binding proteins (SREBPs), which bind an EBOX-like sterol response element (SRE) in the promoters of these genes to activate them (Sakakura et al., 2001; Horton et al., 2002) . SREBPs belong to the EBOX-consensus-binding basic helix-loop-helix-leucine zipper family of transcription factors whose cleavage from the endoplasmic reticulum and nuclear envelope by membrane-bound transcription factor proteases site (MBTPS) 1 and 2 is triggered by sterol cleavage-activating protein (SCAP). When extracellular levels of cholesterol drop, binding of SCAP to SREBPs signals for cleavage to take place allowing these proteins to translocate to the nucleus and activate transcription of their target genes. Expression profiling results indicated that MBTPS1 was upregulated by WT1 in both the HEK293 and M15 experiments (Table 3 and Figure 2b ). While there was no change in SREBP1a Figure 3 Genes regulated by SREBPs. This diagram shows the major metabolic intermediates in the pathways for the synthesis of cholesterol, fatty acids and triacylglycerides. In vivo, SREBP2 preferentially activates genes of cholesterol metabolism, whereas SREBP1c preferentially activates genes of the fatty acid and triglyceride metabolism (Horton et al., 2002) . Genes repressed by WT1 are shaded grey. FPP, farnesyl diphosphate; GPP, geranylgeranyl pyrophosphate levels, SREBP2 was upregulated at 24 and 48 h by WT1-A and upregulated (up to ninefold) at all time points by WT1-D (Figure 2b ). Low-density lipoprotein-related protein 1 (LRP1), a large cell surface multiligandbinding protein and a member of the low-density lipoprotein receptor family, was also repressed by WT1 induction. LRP1 has been proposed to be regulated by SREBP2 in smooth muscle cells (LlorenteCortes et al., 2002) .
Expression of cholesterol genes in the kidney
WT1 plays a critical role during kidney development as reflected by its highly restricted pattern of expression (Pritchard-Jones et al., 1990) . Low levels of WT1 are first detected in the committed MM. As the ureteric bud enters the mesenchyme, WT1 is upregulated in the condensing MM as it undergoes a transition to epithelium. WT1 is then expressed in the developing glomeruli (comma-and S-shaped bodies) with the highest expression seen in the podocytes. To determine if the genes involved in the cholesterol pathway are also expressed in developing structures of the fetal kidney, whole mount in situ hybridization was performed. As these genes are repressed by WT1, it would be expected that they are not expressed in areas where WT1 is expressed. In situ hybridization of 12.5 dpc explanted metanephroi revealed that IDI1, squalene synthase, squalene epoxidase and SCD2 are expressed to varying degrees in the ureteric epithelium as well as parts of the developing nephrons, which will develop into regions ranging from the proximal and distal tubules to the collecting ducts (Figure 4a-l) . In addition, IDI1 is expressed in the interstitium of the metanephros. Expression of these genes does not overlap with the sites of strongest WT1 expression. Section in situ hybridization of SCD2 together with WT1 immunohistochemical staining showed that regions of high WT1 and SCD2 expression were not overlapping (Figure 4s and t). In contrast, SREBP1 (unchanged by WT1) and SREBP2 (upregulated by WT1) show different expression patterns. SREBP1 is found only in the ureteric epithelium and the cells immediately surrounding the tips, while SREBP2 is expressed in the early MM and also throughout the more mature developing nephrons, including parts of the nephron that express WT1. Therefore, the expression patterns of genes repressed by WT1 are separate to that of WT1, whereas regions of SREBP2 expression overlap with that of WT1 in the developing podocytes (Figure 4m-r) . Expression of IDI1, FDFT1, SQLE and SCD2 is seen in varying degrees in the ureteric epithelium (arrow) and in parts of the developing nephrons (double head arrow). SREBP1 is found in the ureteric epithelium (arrow) and the cells immediately surrounding the tips. SREBP2 is expressed in the early MM and also throughout the more mature developing nephrons. Section in situ hybridisation. Transverse sections through E13.5 kidneys were hybridized with an antisense probe to SCD2 (purple) followed by immunohistochemical detection of WT1 with a polyclonal antibody (Dako) (S and T). WT1 expression is seen in the podocyte layer of the developing nephron (open arrow), whereas SCD2 expression is restricted to the presumptive proximal and distal tubules of the developing nephron (double head arrow)
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WT1-binding sites within promoters of the mevalonate pathway
To investigate whether the reduction in steady-state levels of mRNA from multiple members of the mevalonate pathway could result from direct WT1 transcriptional repression, we analysed the immediate promoters (À500 to þ 100) of IDI1, FDFT1, FDPS, SQLE, LSS and SCD2 for the presence of EGR-likebinding sites ( Figure 5) . Most of these genes contained one or multiple predicted EGR1-or WT1-binding sites, with lanosterol synthase very rich in such sites. IDI1 and FDPS did not contain any EGR/WT1 motifs. This does not mean that such sites do not exist in more 5 0 regions of the promoters. IDI1, FDFT1, SQLE, LSS and SCD2 promoters also contained predicted E-BOX motifs, as would be expected for SREBP-regulated genes. This is the first report of a putative SRE within the promoter of SCD2. We then analysed the promoters of SREBP1 and 2, together with MTBPS1 and SCAP1, both of which act to activate SREBP function. SREBP2, SCAP1 and MTBPS1 were found to have putative SREs within their promoters. SREBP1 and SREBP2 contained EGR/ WT1-binding sites, as did SCAP1 and MTBPS1. It is possible, therefore, that WT1 may directly repress members of the mevalonate pathway and activate the SREBPs via DNA binding. As WT1 induction appears to increase SREBP2 mRNA levels, it is also possible that mevalonate/fatty acid synthesis pathway repression occurs via a protein-protein interaction between WT1 and SREBP, as has been previously seen for Dax-1 and SREBP1 (Lopez et al., 2001 ).
WT1 binds SPREBPs
To test this hypothesis, GST-SREBP1a and 2 fusion proteins bound to glutathione agarose beads were incubated with 35 S-labelled WT1-A and D in in vitro protein-protein assays. The beads were subjected to extensive washing and analysed by SDS-PAGE followed by autoradiography. A single band of 52 kDa for WT1-A and 54 kDa for WT1-D was detected indicating that there is a direct interaction between both SREBP1a and 2 and WT1-A and D (Figure 6 ). Constructs containing WT1 deletion mutants were then used in GST pull-down assays to try to identify the specific region of WT1 interacting with the SREBPs. These deletions encompass structural features such as the Nterminal polyglycine run (1-45), the proline-rich region (37-157), functional domains such as the activation domain (158-253) and the zinc-fingers (WT1-ZF and ZF1-4). All deletions constructs except for 182-427 bound convincingly to both SREBP1a and 2. This result indicates that the region in which WT1-ZF and ZFs overlap (amino acids 310-324) may contain the domain that interacts with the SREBPs. Alternatively, there may be more than one region of WT1 that is able to bind the SREBPs within the zinc-finger domain and within the N-terminal segment of the protein.
Discussion
Delineation of genes and gene pathways regulated by WT1 isoforms is likely to elucidate molecules of importance in the aetiology of Wilms' tumour and other WT1-related cancers, as well as in renal development. In this study, we have used two different developmentally appropriate cell lines to identify kidney-specific WT1-responsive genes. HEK293 cells were stably transfected with WT1 to allow inducible expression in response to doxycycline. In contrast, M15 cells were transfected with a WT1 antisense construct to abolish endogenous expression of all WT1 isoforms. Like previous expression profiling analyses of WT1 function (Thate et al., 1998; Lee and Pelletier, 2001; Palmer et al., 2001) , we were unable to confirm changes in the expression of the majority of previously proposed WT1 target genes, with the exception of c-myc and ODC. However, by examining the complementary overlap in expression change elicited by WT1 induction versus repression in these two cell lines, we have demonstrated that the most pronounced changes in mRNA steady-state levels was seen for genes involved in the synthesis of cholesterol and fatty acids. Figure 5 The immediate promoters/5'UTRs (À500 to þ 101 from the start of transcription) of SREBP1, SREBP2 genes involved in their activity (MTBPS1, SCAP1), and genes within the mevalonate or fatty acid synthesis pathways whose steady state was reduced upon WT1 induction were analysed for the presence of EBOX-or EGFR-binding sites. Those EGFR sites defined as WT1 sites are indicated. Promoters were defined using Chip2Promoter (www. genomatic.de) (top panel). Transcription sites were identified using MatInspector (lower panel)
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Although we report here a total of 15 genes with verified expression changes in response to WT1, and supplementary lists of 193 differentially expressed genes, relatively few genes showed a response to WT1 induction/repression with no gene changing more than 15-fold. In the analysis of expression profiling results, it is assumed that the induction of the protein of interest will result in a change in the steady-state levels of mRNA for specific target genes. When your protein of interest is a transcription factor, this is also assumed to result from changes in transcriptional initiation. WT1 is known to bind to RNA as well as DNA. The colocalization of WT1 with the splicing machinery, as assessed by its speckled subnuclear localization (Larsson et al., 1995b) , direct interaction with the splicing factor U2AF65 (Davies et al., 1998) , immunoprecipitation with polyadenylated RNA (Ladomery et al., 1999) and presence in the Cajal bodies associated with Lampbrush chromosomes (Ladomery et al., 2003) , suggests a role for WT1 in RNA metabolism rather than transcriptional regulation. This may include regulation of mRNA maturation, splicing, export to the cytoplasm, stability or delivery to the translational machinery. It is therefore possible that WT1 induction will not significantly alter steady-state levels of target transcripts due to feedback mechanisms. This may explain the absence of significant changes in levels of expression upon WT1 induction both in our hands and as reported by others. Even for those targets identified as having altered steady-state mRNA levels in response to WT1, it remains to be verified that this results from transcriptional or posttranscriptional events.
Cholesterol is supplied to the cell either by receptormediated uptake into the cell, or via the endogenous production of cholesterol from acetyl CoA via the mevalonate pathway. Genes encoding enzymes within the mevalonate pathway are transcriptionally activated by the SREBPs (Sakakura et al., 2001) (Figure 7a) . In this report, we have shown via expression profiling that the steady-state mRNA levels for six genes from this pathway decrease in response to WT1. In contrast, the level of SREBP2 mRNA, and mRNA for MBTPS1, which activates SREBPs via their cleavage from within the ER, is increased by WT1. Putative WT1-binding sites do exist within the promoters of these genes, as well as in the promoter of SCD2 from the fatty acid synthesis pathway. Hence, it is feasible that WT1 may directly repress the transcription of these mevalonate and fatty acid pathway genes (Figure 7b ). However, it would seem paradoxical to activate SREBP2, while repressing a pathway activated by that same protein. The temporal profiles observed would indicate that the induction of SREBP2 by WT1 precedes the repression of members of the mevalonate pathway, possibly indicating that the latter is indirect, whereas SREBP regulation is direct.
In vitro protein-protein assays revealed that both WT1-A and D proteins are able to bind SREBP1a and 2 proteins. There are several precedents in which WT1 alters the activity of a DNA-binding transcription factor via protein-protein interactions. During testis development, WT1 interacts directly with steroidogenic factor 1 GST pull down with purified GST ( þ GST) GST) and GST-SREBP1a fusion proteins attached to glutathioneagarose beads. (c) GST pull down with purified GST ( þ GST) and GST-SREBP2 fusion proteins attached to glutathione-agarose beads. Bound proteins were washed, run on 10% SDS-PAGE gels and visualized by autoradiography. Approximately 10% of the input of each labelled protein is shown on the left-hand side of each gel (SF-1) to markedly increase expression of mullerian inhibitory factor (MIF/MIS) (Nachtigal et al., 1998) . The WT1-SF-1 complex binds to the adjacent WT1-and SF1-binding sites within the MIS promoter and SF-1 interacts with the proline-glutamine-rich region of WT1 (amino acids 8-180), allowing simultaneous SF1 and DNA binding. In the ovaries, the orphan nuclear receptor, DAX-1, antagonizes this functional interaction between WT1 and SF-1 by competing for binding to SF-1, thereby suppressing the induction of MIS expression. WT1 or Dax-1 can also interact with SF-1 in endometriotic stromal cells to inhibit SF-1-mediated activation of the aromatase P450 promoter (Gurates et al., 2002) . Similarly, Dax-1 has been shown to repress both SREBP1a-and SF-1-dependant activation of the high-density lipoprotein receptor (HDL-R) (Lopez et al., 2001) . Incubation of Dax-1 with SREBP1a prevented subsequent binding of SREBP1a to the HDL-R SRE, resulting in a subsequent decrease in promoter activity.
Based on the ability of the WT1 protein to bind SREBPs, it is possible that an interaction between WT1 and SREBP proteins may prevent the SREBPs from binding to the SREs in the promoters of their target genes, thereby inhibiting transcription (Figure 7c) . However, the prevention of SREBP binding would not necessarily result in a repression of SREBP target gene transcription. Alternatively, an SREBP-WT1 interaction that does not prevent SRE binding may change SREBPs from transcriptional activators to repressors (Figure 7d ). This may or may not involve simultaneous DNA binding by WT1 via the putative WT1-binding sites identified in these promoters (Figure 7e and f) .
Although first expressed in the metanephric mesenchyme as a whole, WT1 expression increases as this mesenchyme epithelializes to form the nephron. WT1 expression increases again in the proximal end of the S-shaped bodies as the podocytes are formed. WT1 is thought to function at this point in development to slow proliferation and thereby promote differentiation, with the persistence of nonepithelialized blastema in Wilms' tumours, suggesting that a disruption to this process has occurred. The production of cholesterol by the cell is essential for the synthesis of the cell membrane, thereby regulating cellular proliferation. The expression of components of the mevalonate pathway in the presumptive proximal and distal tubules of the forming nephrons is consistent with continued proliferation of these cells as these tubules elongate. Their reduced expression in the WT1-positive primitive podocyte layer is consistent with the terminal differentation of this cell type and supports the observation of mevalonate pathway repression in response to increasing amounts of WT1. SREBP2 expression was seen in the MM, overlapping with both WT1 and the enzymes of the mevalonate pathway. This is also consistent with roles both in activation and repression of these genes in a cell context-dependant fashion.
In additon to cholesterol, the mevalonate pathway generates steroid hormones, vitamin D and bile acids. It is also responsible for the production of isoprenoids, including ubiquinone, heme and the prenylation (farnesylation and geranylation) of proteins. Prenylation is important for the cellular localization and hence activity of the Ras protein superfamily (Fukada et al., 1990) . The hydrophobic prenylic groups anchor the RasGTPases to the intracellular membranes before translocation to the plasma membrane (Magee and Marshall, 1999) . The cellular membrane thus allows the prenylated Ras to take part in specific interactions with other proteins before the signal is transmitted to the nucleus. It has previously been shown that WT1 changes the morphology and rate of proliferation of ras-transformed NIH3T3 cells (Luo et al., 1995) , indicating a growth suppressive ability for WT1 via a reduction in ras activity. Hence, rather than a simple reduction in cholesterol production, the inhibition of the mevalonate pathway by WT1 may primarily act to reduce prenylation of proteins such as ras, thereby controlling cellular proliferation.
Inhibition of the mevalonate pathway is the mode of action of a number of currently used drugs, including the statins and farnesyltransferase inhibitors (FTIs). Statins are inhibitors of HMG CoA reductase, a ratelimiting enzyme in the mevalonate pathway. FTIs inhibit the process of farnesylation. While initially developed for cholesterol reduction, statins and FTIs are now being used in the treatment of cancer. Here, they act by inhibition of protein prenylation of RhoA, resulting in the subsequent disruption of RhoA-dependant cell signalling, including the suppression of RhoA/ ROCK regulation of the actin cytoskeleton and the RhoA/FAK/AKT regulation of cell proliferation and invasive capacity (Denoyelle et al., 2003) . This results in decreased cell proliferation, motility and invasiveness. Experimental studies using models of progressive renal damage have shown that statins reduce glomerulosclerosis, thus preventing progressive renal failure (Oda and Keane, 1999) . Although the mechanism by which statins prevent renal damage is unknown, they also appear to be mediated by suppressed prenylation of RhoA-dependant cell signalling. Studies on murine glomerular mesangial cells suggest that Lovastatint can inhibit synthesis of farnesol, a key isoprenoid metabolite, which modulates Ras-mediated cell signalling events associated with mesangial cell proliferation (Bassa et al., 1999) . It is interesting to note, therefore, that a reduction in WT1 expression or imbalance of WT1 isoform production is associated with the development of mesangial sclerosis in conditions such as Denys-Drash syndrome and diffuse mesangial sclerosis. However, WT1 did not alter steady-state levels of HMG CoA reductase mRNA, rather preferentially repressing those enzymes further down in the pathway.
In conclusion, by comparing the complementary expression profiles of developmentally relevant cell lines in which WT1 expression was induced or repressed, we have demonstrated a reduction in steady-state mRNA levels of enzymes of the mevalonate cholesterol synthesis and fatty acid synthesis pathways. This repression may result from a direct protein-protein interaction between WT1 and SREBPs, with this interaction converting the SREBPs from transcriptional activators to repressors. These results suggest that the tumour suppressor activities of WT1 may result from repression of the mevalonate pathway, possibly simply by suppressing cellular division, or by disrupting ras superfamily activity via alterations in protein prenylation. Clarification of the role of the mevalonate pathway in Wilms' tumour is likely to have clinical implications for the use of inhibitors of this pathway, such as statins and FTIs, on this condition.
Materials and methods
Cell lines
Human embryonic kidney 293 (HEK293) Tet-On cells were purchased from Clontech and cultured in Dulbecco's modified Eagle's medium with tetracycline-free fetal bovine serum (GIBCO BRL). These were transfected with pcDNA3 mammalian expression constructs containing full-length murine WT1-A or WT1-D. Stable clones were selected using 250 mg/ml G418 and 0.4 mg/ml puromycin. Cells were induced to produce WT1-A or D by the addition of 1 mg/ml doxycycline for up to 48 h. Western blot analysis, using an N-terminal WT1 monoclonal antibody, 6F-H2 (Dako), was used to verify the onset of WT1 protein production by addition of doxycycline.
M15 cells were grown in Dulbecco's modified Eagle's medium, 10% fetal bovine serum, 10 mM L-glutamine and 10 mM penicillin-streptavidin. These were transfected with a 1.5 kb Sau3A1 fragment of the murine WT1 cDNA, encompassing 40 bp of 5 0 UTR, the ATG start codon utilized in the production of isoforms A-D, the termination codon and approximately 110 bp of 3 0 UTR, cloned into the BamH1 site of pcDNA3 in an antisense direction. Stable clones were selected using 500 mg/ml G418.
Expression profiling
Total RNA was isolated from trypsinized HEK293 cells at eight time points after induction of WT1 A or D (0-48 h) with doxycycline using the Qiagen RNAeasy columns (Qiagen), according to the manufacturer's directions. RNA was extracted in the same way from wild-type M15 cells and M15 cells transfected with the WT1 antisense construct. Total RNA concentration was measured by spectrophotometry and run on agarose gels to assess RNA quality. In the case of the human HEK293 expression profiling, temporal profiles were generated by comparing multiple time points after induction with doxycycline to a common reference RNA (parental HEK293 cell line). In all, 40 mg of RNA from the test and reference samples was reverse transcribed in the presence of Cy3-dUTP or Cy5-dUTP, respectively (Amersham), as previously described (Grimmond et al., 2000) . These samples were then pooled and cohybridized to OCI human 19 K 2.2 arrays, containing approximately 19 008 double-spotted cDNAs. In the case of expression profiling of the M15 mouse cell line, a direct pair wise comparison was carried out between M15 wildtype and M15 WT1as total RNAs. These labelled samples were hybridized to SRC (Special Research Centre for Functional and Applied Genomics) mouse NIH_NIA version 1 microarrays containing 15 264 cDNAs (Tanaka et al., 2000) . All Cy3 and Cy5 hybridization signals were collected using a GMS418 Array Scanner. Intensity and background data for each element was calculated for all elements on the array using the Imagene 4.1 (BioDiscovery Inc.). Signal intensities were imported into GeneSpring V3.2.2 (Silicon Genetics Inc.) and for each hybridization, each gene's measured intensity was divided by its control channel value at each time point. Intensity-dependant normalization was applied, where the ratio was reduced to the residual of the Lowess fit of the intensity versus ratio curve. Finally, ratio data from multiple spots on each array plus experimental replicates were averaged and a mean ratio of 1.8-fold was used as the cutoff for differential expression. Full documentation of cDNA array fabrication, gene content, experimental procedures and all results is available in accordance with MIAME guidelines at http://kidney.scgap.org/base.
Northern analysis
Total RNA (20 mg) isolated as described above was separated on a 3% formaldehyde/agarose gel and transferred to a nylon membrane (Osmonics). cDNA probes were labelled with [ 32 P]dCTP using the Rediprime kit (Amersham). Hybridization was performed in Church and Gilbert buffer (0.5 M sodium phosphate buffer, 7% SDS, 1% bovine serum albumin) overnight at 651C. The blots were then washed to a final stringency of 0.1 Â SSC/0.1% SDS at 551C and signals were detected using a Phosphor imaging screen (Molecular Imager Systems). Blots stripped with boiling 0.1% SDS and reprobed with a 28S probe and analysed using ImageQuant 5.0 software to correct for variation in RNA loading.
Wholemount and section in situ hybridization
Embryonic metanephroi were dissected from 11.5 or 12.0 dpc outbred CD1 mouse embryos into ice-cold Leibovitz's L15 media (Invitrogen). Explanted metanephroi were grown for 1-3 days on Costar Transwell polycarbonate inserts (Corning) with a membrane pore size of 3.0 mm at 371C with 5% CO 2 in either MEM media (Invitrogen), supplemented with 10% fetal calf serum and 20 mM glutamine, or MEM/Hams F12 media (Invitrogen) supplemented with 50 mg/ml transferrin and 20 mM glutamine. At the end of the culture period, metanephroi were fresh frozen in OCT for cryosectioning (14 mm) or fixed in 4% paraformaldehyde at 41C in PBS overnight for wholemount in situ hybridization.
All probes for in situ hybridization were transcribed from linearized templates using either T7 or SP6 RNA polymerase (Roche) and labelled with digoxygenin (DIG)-labelled UTP (Roche), according to the maufacturer's specifications. Both wholemount and section in situ hybridizations were performed as previously described (Christiansen et al., 1995) with modifications including hybridization at 651C and reducing post-antibody washes to 30 min each. After the in situ hybridization colour reaction, kidney sections were washed in PBS and immunohistochemistry was performed using the Vectastain ABC kit (Vector Laboratories), according to the instructions provided. The DAB colour reaction was initiated by using a 10 min preincubation in 0.03% H 2 O 2 in PBS, followed by incubation in 0.03% H 2 O 2 with 500 mg/ml DAB in PBS until the desired colour was obtained, approximately 30 s-3 min. WT1 was detected with an anti-human WT1 monoclonal mouse antibody (Dako), at a 1 : 100 dilution. Kidney explants were removed from the filters before photographing and mounted on slides under a coverslip. Photographs were taken using Kodak Elite Ektachrome 320 T film and a Leica MZ8 stereomicroscope/MPS48 photomicrographic system.
Definition and analysis of promoters for transcription factor-binding sites
The Genomatix suite of bioinformatic tools (www.genomatix. de) was used to both define the promoters and to search for specific transcription factor-binding sites. Accession numbers used for each gene either related to the clone ID on the microarray chips used or were selected from Unigene. All sequences analysed were human with the exception of SCD2 (mouse) for which there is no human ortholog described. Chip2promoter was used to define 500 bp of 5 0 UTR from the start of transcription. A region of 601 bps, from À500 to þ 100 from the transcriptional start site was searched using MatInspector (Quandt et al., 1995) . Only V$EGFR (EGR/ nerve growth factor induced protein C and related factors; 15 bp length) and V$EBOX (E-box-binding factors; 17 bp length) matrix families were assigned. The WT1 sites were differentiated from others within the EGFR family according to the defined profile nngngTGGGsgcgns, with bold indicating basepairs with a high information content and basepairs in capital letters defining the core sequence used for searching. All EBOX motifs were annotated without subdefining those most likely to conform to an SREBP.01, SREBP.02 or SREBP.03 profile. MatInspector was performed at an optimization value of 0.80.
In vitro protein-protein-binding assays Glutathione S-transferase (GST)-SREBP1a and 2 constructs were made by PCR amplification with Pfu polymerase (Stratagene) of nucleotides 161-1636 of SREBP1a and 100-1678 of SREBP2, which represent the NH 2 -terminal segment (active segment) of the SREBP proteins. The resulting PCR products were then inserted in-frame with the GST coding region in the pGEX3T plasmid (Amersham). The fusion proteins were expressed in Escherichia coli strain DH5aF 0 . Cultures were grown to A 600 of 0.6, induced by adding isopropyl-1-thio-b-D-galactopyranoside to a final concentration of 1 mM and grown for an additional 2 h at 371C. Cells were then harvested by centrifugation. The cell pellets were then resuspended in NETN (100 mM NaCl, 20 mM Tris, pH 8, 1 mM EDTA, 0.5% Nonidet P-40), lysed by sonication and the cell debris was removed by ultracentrifugation. The supernatant was then incubated with 1 : 1 slurry of glutathioneagarose (Sigma) on a rotating wheel at 41C for 30 min, followed by extensive washing with PBS. The expression of the fusion protein was verified by SDS-PAGE analysis followed by staining with Coomassie Blue as well as Western blot with an anti-GST antibody (kindly provided by Dr Paul Kroon).
Using the TNT-coupled transcription/translation kit (Promega), rabbit reticulocyte lysates were incubated with 0.5 mg of plasmids containing either WT1-A, WT1-D or WT1 deletion constructs (previously described in Holmes et al., 1997) . The synthesis of full-length labelled products was verified by SDS-PAGE and autoradiography. To 40 ml of the indicated GST fusion protein extract, 200 ml of NETN buffer þ 5 mg ethidium bromide þ 100 mg bovine serum albumin and 5 ml of 35 Smethionine (Amersham)-labelled WT1-A, D or deletions were added followed by an incubation on a rotating wheel for 1 h. The bound GST fusion protein was pelleted in a microcentrifuge and nonspecifically bound proteins were removed by washing the pellets four times with 1 ml of buffer. The specifically bound proteins were pelleted, resuspended in sample buffer, and analysed by SDS-PAGE followed by autoradiography.
